Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Fineline Cube Feb 11, 2026
Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026
Company Deals Medical Device

Finland’s Bone Index Partners with Lynx Financial for APAC and North American Market Expansion

Fineline Cube Aug 21, 2024

HELSINKI—Bone Index, a pioneering medical technology company headquartered in Finland, has announced the successful completion...

Company

Chengdu Kanghua Biological Products Soars with 16.81% YOY Revenue Growth in H1 2024 Report

Fineline Cube Aug 21, 2024

CHENGDU—Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841) has reported a significant upswing in its...

Company Drug

Johnson & Johnson’s Rybrevant-Lazclude Combo Approved by FDA for First-Line NSCLC Treatment

Fineline Cube Aug 21, 2024

NEW YORK—Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has secured a significant regulatory milestone...

Company

CSPC Pharmaceutical Group Reports Modest Gains in H1 2024 with Patent Medicines Driving Revenue

Fineline Cube Aug 21, 2024

HONG KONG—CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced its financial results for the first...

Company Drug

AstraZeneca’s Strensiq Gains Approval for Rare Disease Therapy in Guangdong Under “Hong Kong-Macau Drug and Device Access”

Fineline Cube Aug 21, 2024

LONDON—AstraZeneca (NASDAQ: AZN, LON: AZN) , a leading UK-based pharmaceutical company, has announced that its...

Company Deals

Johnson & Johnson to Acquire Israel’s V-Wave Ltd. in a Deal Valued Up to $1.7 Billion

Fineline Cube Aug 21, 2024

NEW YORK—Johnson & Johnson (NYSE: JNJ), a multinational healthcare giant based in the US, has...

Policy / Regulatory

China’s National Drug Alliance Procurement Office Imposes Sanctions on Six Firms Over Collusion in Bromhexine Bidding

Fineline Cube Aug 21, 2024

BEIJING—The National Drug Alliance Procurement Office, which oversees the Volume-Based Procurement (VBP) program, has announced...

Company Medical Device

MicroPort MedTech’s ReeAmber Catheter Wins NMPA Nod for Peripheral Artery Treatments

Fineline Cube Aug 20, 2024

SHANGHAI—Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical device...

Company

CGP’s 2024 Interim Report Shows Robust Growth in Revenues and Profits, Highlighting R&D Focus

Fineline Cube Aug 20, 2024

HONG KONG—China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has released its interim...

Company

Genmab CEO Signals Potential for China Partnership as BioNTech Exits acasunlimab Collaboration

Fineline Cube Aug 20, 2024

COPENHAGEN—In a strategic pivot following BioNTech (NASDAQ: BNTX)’s withdrawal from their co-development partnership on the...

Company Drug

Hasten Biopharmaceutical Gains NMPA Nod for Somatostatin Marketing Rights in China

Fineline Cube Aug 20, 2024

BEIJING—Hasten Biopharmaceutical Co., Ltd, a biopharmaceutical company supported by the CBC Group, has received approval...

Company Drug

Yipinhong Pharmacy’s AR882 Earns FDA Fast-Track Status for Gout Treatment

Fineline Cube Aug 20, 2024

BEIJING—China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced that its novel drug AR882 has...

Company Deals

Sichuan Kelun Pharmaceutical’s H1 2024 Report Highlights MSD Collaboration Milestones

Fineline Cube Aug 20, 2024

CHENGDU—Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has released its financial report for the first...

Policy / Regulatory

NHSA Flags Concerns Over Pricing of MicroPort’s Castor Aortic Stent Graft System

Fineline Cube Aug 20, 2024

BEIJING—The National Healthcare Security Administration (NHSA) has issued an open letter expressing concerns over the...

Company Drug

Astellas Pharma’s Padcev Receives NMPA Approval for Urothelial Cancer Treatment

Fineline Cube Aug 20, 2024

TOKYO—Astellas Pharma Inc. (TYO: 4503) has announced that its anti-HER3 antibody-drug conjugate (ADC), Padcev (enfortumab...

Company Drug

BioNTech’s BNT326/YL202 Clears FDA Hurdle, Advancing in Clinical Trials for Solid Tumor Treatment

Fineline Cube Aug 20, 2024

FRANKFURT—BioNTech SE (NASDAQ: BNTX), a leading German biotechnology company, has announced that the US Food...

Company Deals

Jiangsu Hengrui Pharmaceuticals Expands R&D Footprint with Jinan Innovation Zone Partnership

Fineline Cube Aug 20, 2024

JINAN—The management committee of the Jinan Innovation Zone has entered into a strategic partnership with...

Company Medical Device

China’s NMPA Grants Medical Device License to DaAn Gene’s Monkeypox Detection Kit

Fineline Cube Aug 20, 2024

GUANGZHOU—DaAn Gene Co., Ltd, a subsidiary of Sun Yat-sen University based in China (SHE: 002030),...

Company Deals

Genesis MedTech’s J-VALVE System Transfers to Edwards Lifesciences, Marking a New Era in Aortic Valve Treatment

Fineline Cube Aug 20, 2024

SINGAPORE—In a strategic move to strengthen its position in the global medical device market, Edwards...

Company Drug

Changchun High & New Technology Secures NMPA Approval for Turner Syndrome Treatment

Fineline Cube Aug 20, 2024

CHANGCHUN—Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading biopharmaceutical company in...

Posts pagination

1 … 268 269 270 … 622

Recent updates

  • China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
  • Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
  • Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
  • Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
  • Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.